Kurs & Likviditet
Kalender
| 2024-08-07 | Kvartalsrapport 2024-Q2 |
| 2024-06-06 | X-dag ordinarie utdelning BIOBV 0.00 EUR |
| 2024-06-05 | Årsstämma 2024 |
| 2024-02-14 | Bokslutskommuniké 2023 |
| 2023-08-09 | Kvartalsrapport 2023-Q2 |
| 2023-06-15 | X-dag ordinarie utdelning BIOBV 0.00 EUR |
| 2023-06-14 | Årsstämma 2023 |
| 2023-03-22 | Bokslutskommuniké 2022 |
| 2022-08-10 | Kvartalsrapport 2022-Q2 |
| 2022-06-16 | X-dag ordinarie utdelning BIOBV 0.00 EUR |
| 2022-06-15 | Årsstämma 2022 |
| 2022-03-09 | Extra Bolagsstämma 2022 |
| 2022-02-16 | Bokslutskommuniké 2021 |
| 2021-08-11 | Kvartalsrapport 2021-Q2 |
| 2021-04-22 | X-dag ordinarie utdelning BIOBV 0.00 EUR |
| 2021-04-21 | Årsstämma 2021 |
| 2021-02-17 | Bokslutskommuniké 2020 |
| 2020-08-12 | Kvartalsrapport 2020-Q2 |
| 2020-04-23 | X-dag ordinarie utdelning BIOBV 0.00 EUR |
| 2020-04-22 | Årsstämma 2020 |
| 2020-02-19 | Bokslutskommuniké 2019 |
| 2019-08-14 | Kvartalsrapport 2019-Q2 |
| 2019-04-25 | X-dag ordinarie utdelning BIOBV 0.00 EUR |
| 2019-04-24 | Årsstämma 2019 |
| 2019-02-20 | Bokslutskommuniké 2018 |
| 2018-08-22 | Kvartalsrapport 2018-Q2 |
| 2018-08-16 | Extra Bolagsstämma 2018 |
| 2018-04-26 | X-dag ordinarie utdelning BIOBV 0.00 EUR |
| 2018-04-25 | Årsstämma 2018 |
| 2018-02-28 | Bokslutskommuniké 2017 |
| 2017-07-27 | Kvartalsrapport 2017-Q2 |
| 2017-04-27 | X-dag ordinarie utdelning BIOBV 0.00 EUR |
| 2017-04-26 | Årsstämma 2017 |
| 2017-02-02 | Bokslutskommuniké 2016 |
| 2016-10-20 | 15-10 2016-Q3 |
| 2016-08-10 | Kvartalsrapport 2016-Q2 |
| 2016-05-12 | Kvartalsrapport 2016-Q1 |
| 2016-04-26 | X-dag ordinarie utdelning BIOBV 0.00 EUR |
| 2016-04-25 | Årsstämma 2016 |
| 2016-02-25 | Bokslutskommuniké 2015 |
| 2015-10-22 | Kvartalsrapport 2015-Q3 |
| 2015-08-20 | Kvartalsrapport 2015-Q2 |
| 2015-05-07 | Kvartalsrapport 2015-Q1 |
| 2015-04-21 | X-dag ordinarie utdelning BIOBV 0.00 EUR |
| 2015-04-20 | Årsstämma 2015 |
| 2015-02-26 | Bokslutskommuniké 2014 |
| 2014-10-23 | Kvartalsrapport 2014-Q3 |
| 2014-08-21 | Kvartalsrapport 2014-Q2 |
| 2014-05-08 | Kvartalsrapport 2014-Q1 |
| 2014-04-15 | X-dag ordinarie utdelning BIOBV 0.72 EUR |
| 2014-04-14 | Årsstämma 2014 |
| 2014-02-27 | Bokslutskommuniké 2013 |
| 2013-10-24 | Kvartalsrapport 2013-Q3 |
| 2013-08-08 | Kvartalsrapport 2013-Q2 |
| 2013-04-25 | Kvartalsrapport 2013-Q1 |
| 2013-04-09 | X-dag ordinarie utdelning BIOBV 0.50 EUR |
| 2013-04-08 | Årsstämma 2013 |
| 2013-02-27 | Bokslutskommuniké 2012 |
| 2012-10-25 | Kvartalsrapport 2012-Q3 |
| 2012-08-16 | Kvartalsrapport 2012-Q2 |
| 2012-04-26 | Kvartalsrapport 2012-Q1 |
| 2012-04-12 | X-dag ordinarie utdelning BIOBV 1.00 EUR |
| 2012-04-11 | Årsstämma 2012 |
| 2012-02-29 | Bokslutskommuniké 2011 |
| 2011-11-23 | Extra Bolagsstämma 2011 |
| 2011-10-20 | Kvartalsrapport 2011-Q3 |
| 2011-08-18 | Kvartalsrapport 2011-Q2 |
| 2011-04-28 | Kvartalsrapport 2011-Q1 |
| 2011-04-14 | X-dag ordinarie utdelning BIOBV 0.00 EUR |
| 2011-04-13 | Årsstämma 2011 |
| 2011-03-01 | Bokslutskommuniké 2010 |
| 2010-04-26 | X-dag ordinarie utdelning BIOBV 0.00 EUR |
| 2009-04-21 | X-dag ordinarie utdelning BIOBV 0.00 EUR |
| 2008-04-22 | X-dag ordinarie utdelning BIOBV 0.00 EUR |
| 2007-04-20 | X-dag ordinarie utdelning BIOBV 0.00 EUR |
| 2006-04-21 | X-dag ordinarie utdelning BIOBV 0.00 EUR |
| 2005-04-22 | X-dag ordinarie utdelning BIOBV 0.00 EUR |
| 2004-04-16 | X-dag ordinarie utdelning BIOBV 0.00 EUR |
| 2003-04-10 | X-dag ordinarie utdelning BIOBV 0.00 EUR |
| 2002-04-02 | X-dag ordinarie utdelning BIOBV 0.00 EUR |
| 2001-03-28 | X-dag ordinarie utdelning BIOBV 0.00 EUR |
| 2000-04-07 | X-dag ordinarie utdelning BIOBV 0.00 EUR |
| 1999-04-22 | X-dag ordinarie utdelning BIOBV 0.00 EUR |
Beskrivning
| Land | Finland |
|---|---|
| Lista | Small Cap Helsinki |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Biohit Oyj Press release June 14, 2024 at 10:00 AM local time
BIOHIT STRENGTHENS THE STRATEGIC AND OPERATIONAL PERFORMANCE OF R&D
Biohit Oyj is renewing its organization as part of its 2024-2028 growth strategy. The organizational change aims to strengthen the strategic and operational performance of R&D. The changes enter into force on August 12, 2024.
Biohit’s R&D Director and Member of the Management Team, Panu Hendolin, Ph.D. (Molecular Medicine), has been appointed the company’s Chief Technology Officer. In addition to strategic management of R&D, Hendolin will in the future be responsible for instruments and monoclonal antibodies. Hendolin will continue as a Member of Biohit’s Management Team.
Marika Karjalainen, M.Sc. (Biochemistry), has been appointed as the new R&D Director. Karjalainen will be responsible for the operational management of R&D. Karjalainen transfers to Biohit from Aiforia Technologies Oyj, where she has worked, for example, as Senior Manager of Regulatory Affairs. Karjalainen is an important Biohit returnee, she worked as a project manager in the company in 2018-2021. Karjalainen has also worked in R&D-related positions at VTT Technical Research Centre of Finland and Orion Diagnostica.
“R&D plays a crucial role in building a competitive product portfolio and achieving growth targets. Differentiating and clarifying strategic and operational roles will ensure prioritization and completion of R&D projects in line with the strategy”, says Biohit’s CEO Jussi Hahtela.
BIOHIT OYJ
Additional information:
CEO Jussi Hahtela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
Biohit in brief
Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group.
https://www.biohithealthcare.com/en